-
October 21, 2022 Patent Controversies in PsychedelicsWhat investors need to know about the intellectual property behind medicine’s next big growth area
-
October 17, 2022 Math Over Myth: Compass and Revive Release Phase 3 Updates but Stocks DropMath over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and...
-
October 13, 2022 Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS,...
-
October 6, 2022 Math Over Myth: Weekly Psychedelic Stocks News RoundupGet the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin...
-
September 30, 2022 Math Over Myth: September Psychedelic Stock News RoundupTrack the monthly performance of the psychedelic stock sector with our Math over Myth Stock...
-
September 28, 2022 Math Over Myth: MindMed’s Self Destructive Stock MissionPsychedelic stock MindMed enters free fall as news of a private equity offering of common...
-
September 21, 2022 Math Over Myth: Psychedelic Stock HAVN Life CollapsesThe psychedelic corporate shakeout continues as another company, HAVN Life Sciences, folds due to lack...
-
September 19, 2022 End of Life: Psychedelics in Palliative CareWe interview Dr. Paul Thielking, Chief Science Officer of Numinus, about the use of psychedelics...
-
September 14, 2022 Math Over Myth: Spotlight on MindMedIn the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split...
-
September 9, 2022 Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASSIf you want to invest in psychedelic stocks, ignore the hype and look at the...
